Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | GUSB | P08236 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307298 | 0.77 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4078861 | 0.75 | SMN1; SMN2 (0.66) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4075241 | 0.74 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL13496401 | 0.73 | ALDH1A1 (0.84) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL13496402 | 0.73 | KMT2A (0.83) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL12594548 | 0.73 | ALDH1A1 (0.83) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL13496413 | 0.72 | KMT2A (0.82) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL13496417 | 0.71 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL13496406 | 0.70 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL14068803 | 0.70 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | ALDH1A1 1055/4885MEN1 3178/4885KMT2A 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.